The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

In the world of biotechnology, few stories resonate as strongly as that of Pasithea Therapeutics Corp. (NASDAQ: KTTA). On Thursday, the stock saw an impressive surge of +80.31%, reaching $6.90 during ...

If these preliminary findings are more widely applicable, opioid use disorder would be added to the long list of ailments potentially reduced by Ozempic.

The Wayne County commissioners heard stories of recovery from people helped by the free services of the county Drug & Alcohol ...